secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-09-28T20:44:17+00:00
Accession:  0001213900-26-104101
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Jasper Therapeutics CFO Herb Cross resigns Oct 9; CEO Jeet Mahal takes interim PFO role
--------------------------------------------------------------------------------

- CFO, principal financial and accounting officer and corporate secretary Herb Cross resigned effective October 9, 2026 to pursue other professional endeavors.
- Board acted September 28, 2026: CEO Jeet Mahal named interim Principal Financial Officer and VP Finance Rick Ruiz interim Principal Accounting Officer.
- Chief Operating Officer Matthew Ros was appointed interim Corporate Secretary; all three appointments take effect on Cross's resignation date.
- Ruiz, 62, joined Jasper in 2024 after VP Finance roles at Atreca and controller work at Audible Magic; he keeps a $364,000 base salary and equity eligibility.
- No new equity award was granted to Ruiz for the interim promotion, and no permanent CFO replacement was named.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026104101/0001213900-26-104101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026104101/ea0306856-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-104101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer